SEL 110

Drug Profile

SEL 110

Alternative Names: SEL-110; SVP Rapamycin

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Selecta Biosciences
  • Class Anti-infectives; Antifungals; Antineoplastics; Gene therapies; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunomodulators; Methylmalonyl CoA mutase stimulants; Ornithine carbamoyltransferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Immunological disorders
  • Research Inborn urea cycle disorders; Methylmalonic acidaemia

Most Recent Events

  • 31 Oct 2016 Preclinical pharmacodynamics data released by Selecta Biosciences
  • 19 Jul 2016 Selecta Biosciences establishes CRADA with the National Human Genome Research Institute and Massachusetts Eye and Ear for the development of SEL 110 combined with Anc80 vector in Methylmalonic acidaemia before July 2016
  • 19 Jul 2016 Early research in Inborn urea cycle disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top